Lipid-lowering drugs and cancer: an updated perspective.
Pharmacol Rep
; 76(1): 1-24, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-38015371
ABSTRACT
Statins and non-statin medications used for the management of dyslipidemia have been shown to possess antitumor properties. Since the use of these drugs has steadily increased over the past decades, more knowledge is required about their relationship with cancer. Lipid-lowering agents are heterogeneous compounds; therefore, it remains to be revealed whether anticancer potential is a class effect or related to them all. Here, we reviewed the literature on the influence of lipid-lowering medications on various types of cancer during development or metastasis. We also elaborated on the underlying mechanisms associated with the anticancer effects of antihyperlipidemic agents by linking the reported in vivo and in vitro studies.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Dislipidemias
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Pharmacol Rep
Ano de publicação:
2024
Tipo de documento:
Article